[Comparison of Therapeutic Effects of Low-Dose Versus High-Dose Interferon Alpha-2B Treatment on Chronic Myelocytic Leukemia: a Prospective Randomized Study].

Jin-wei Du,Ping Zhu,Ding Tian,Zuo-ren Dong,Shu-lian Yang,Song-bo Li,Ya-hui Tang,Hui Liu,Xi-nan Cen,Ying Zhang,Qiang Zhu,Yu-lin Zhu,Ying Yang,Dong-xia Wang,Zhao Wang,Hua Cui,Yi-gai Ma,Wen-ming Chen,Fu-qiang Liu,Jian Ma,Jing-wen Wang,Ti Shen,Wan-ming Da

DOI: https://doi.org/10.3760/j:issn:0376-2491.2005.19.003

2005-01-01

Abstract:OBJECTIVE:To compare the therapeutic effects of low-dose and high-dose interferon alpha-2b (IFN) treatment on chronic myelocytic leukemia (CML).METHODS:A real-time quantitative reverse transcriptase PCR (RQ-PCR) method was established to detect the fusion gene bcr-abl expression, thereby studying the reduction of leukemic cells. Thirty newly diagnosed CML patients, 21 males and 9 females, aged 14 - 69, were treated with hydroxyurea to keep the white blood cell count less than 20 x 10(9)/L, and then randomized into 2 groups: high-dose IFN group receiving IFN alpha-2b 5MIU 6 times per week for 3 - 6 months and low-dose IFN group receiving IFN alpha-2b 3MIU every other day for 3 - 6 months. Bone marrow was collected every month to Real-time PCR was used to detect the expression of bcr-abl mRNA. Mononuclear cells were isolated and RNA was extracted to detect the expression of fusion gene bcr-abl and a control gene GAPDH. The results were reported as the number of bcr-abl copies/GAPDH copy.RESULTS:The established real-time quantitative PCR method could detect the bcr-abl molecules as low as 50 copies. The intra-assay coefficient of variation (CV) was less than 5% and the inter-assay CV was 5.13%. The median bcr-abl fusion gene expression level of 30 CML patients before IFN therapy was 0.098 (range: 0.010 - 5.799). The bcr-abl expression level decreased by 19.37% and 24.86% in the low-dose and high-dose IFN groups respectively after 3 months' therapy. No significant difference was observed between the two groups (P = 0.398). Relatively more side effects were observed in the high-dose IFN group than in low-dose group.CONCLUSION:RQ-PCR is a reliable method to monitor CML therapy by analyzing fusion gene bcr-abl expression. There is a difference in bcr-abl fusion gene expression levels among the newly diagnosed patients, and low-dose IFN is as effective as high-dose IFN in reducing bcr-abl expression but with less side effects.